Dr. Al-Batran on Paclitaxel Plus Everolimus in Gastric Cancer

Salah-Eddin Al-Batran, MD
Published: Monday, Jan 30, 2017



Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research — Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

This was a randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

The study aimed to improve outcomes of patients by adding everolimus to paclitaxel chemotherapy in patients who have received prior lines of chemotherapy. Those with gastric cancer were administered either paclitaxel plus everolimus or paclitaxel monotherapy plus placebo.

In the population studied, the addition of everolimus did not improve progression-free survival or overall survival, except in a small subset of patients. The study was stopped prematurely due to being under enrollment.
 


Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research — Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

This was a randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

The study aimed to improve outcomes of patients by adding everolimus to paclitaxel chemotherapy in patients who have received prior lines of chemotherapy. Those with gastric cancer were administered either paclitaxel plus everolimus or paclitaxel monotherapy plus placebo.

In the population studied, the addition of everolimus did not improve progression-free survival or overall survival, except in a small subset of patients. The study was stopped prematurely due to being under enrollment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x